Replace what’s missing in VWD

VWF is essential to primary hemostasis. High molecular-weight von Willebrand factor

(HMW-VWF) multimers accomplish most of the VWF activity1

The process of blood coagulation has two distinct stages of hemostasis: primary hemostasis and secondary hemostasis. While factor VIII (FVIII) has a role in secondary hemostasis, von Willebrand factor protein is a key component in primary hemostasis.2

Von Willebrand factor (VWF) plays an essential role in primary hemostasis. People with von Willebrand disease (VWD) have an insufficient amount of VWF protein in the blood, or VWF that is defective. This deficiency in VWF interferes with proper coagulation, leading to excessive or prolonged bleeding.1

VWF is a multimeric compound, with multimers ranging in molecular weight from low to ultra-high. The size of VWF multimers directly correlates with their in vitro function. High molecular weight (HMW) VWF multimers are more effective in supporting primary homeostasis, whereas low molecular weight (LMW) multimers are less functionally active.1

Nurse with clipboard

HMW-VWF multimers are associated with increased hemostatic activity and shortened bleeding time3

VWF replacement therapy is an important treatment for VWD. Restoring active VWF
levels results in shortened bleeding time and correction of the coagulation abnormality.4

HMW-VWF multimers promote effective collagen-binding

When the vessel is injured, several actions occur to form the initial hemostatic plug1:

  • VWF unfolds from its inactivated pretzel-like shape, exposing A1 domains (platelet receptors)
  • Collagen binds with A3 domains (collagen-binding sites)

HMW-VWF multimers have more A3 domains and A1 domains than LMW-VWF multimers, allowing more bonds to form.1

Graphic demonstrating collagen binding

HMW-VWF multimers promote effective platelet adhesion

At the same time, platelets rush to the injury site, forming bonds with A1 domains.1

Graphic demonstrating platelet adhesion

HMW-VWF multimers promote effective platelet aggregation

The platelet bridges and VWF form layers, known as the initial hemostatic plug, which stop the bleeding at the injury site.1

Successful completion of both stages of hemostasis results in the final step of the clotting process, the formation of a stable hemostatic plug.

graphic demonstrating platelet aggregation

The multimeric pattern of HUMATE-P very closely resembles normal human plasma (NHP)

A densitometric analysis of various FVIII/VWF concentrates and normal human plasma (NHP) revealed that HUMATE-P contains a high percentage of HMW-VWF multimers—as does NHP—and is capable of correcting the hemostatic defect in patients with VWD.5

Densitometric analysis of HUMATE-P, NHP, and various other VWF agents

View an animated densitometric analysis comparing various VWF/FVIII concentrates and normal human plasma

HUMATE-P (represented in the graph by the blue line) had the highest content of HMW-VWF multimers among VWF products tested, and its multimer pattern was most like that of NHP

The multimer patterns of products A, G, H, and E (represented in the densitometric analysis by the red, green, orange, and yellow lines, respectively) differ from that of NHP

The multimeric pattern of HUMATE-P very closely resembles NHP

HMW multimers are critical for hemostasis— they shorten bleeding time2,4


homology with NHP2

Graphic demonstrating high-molecular-weight multimer comparison in densitometric analysis

Effective bleed control with VWF+FVIII in a single therapy

Everyone who has VWD has a potential FVIII deficiency. Type 3 VWD, the most severe type, is associated with minimal FVIII, and people who have Type 2N VWD also have a FVIII deficit. In Type 1 and the other Type 2 VWD subtypes, FVIII levels can potentially be reduced. Administering VWF and FVIII together can help bleeding resolve quickly.6

Every patient with VWD has a potential FVIII deficiency6


FVIII Normal or Reduced


FVIII Normal or Reduced


FVIII Normal or Reduced


FVIII Normal or Reduced


FVIII Deficit


FVIII Minimal (1–9 IU/dL)

One IU of VWF:Rco or FVIII in HUMATE-P is approximately equal to the amount of VWF:Rco of FVIII in 1.0 mL of NHP

The average ratio of VWF:RCo to FVIII

2.4 to 1

HUMATE-P to NHP ratio equivalent to human plasma
Icon of health shield

30+ years of safe, effective bleed control

Icon of vial

Tools to help simplify VWF dosing

  1. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. Haemophilia. 2008;14(Suppl 5):11-26.
  2. Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2013;25:206-216.
  3. Metzner HJ, Hermentin P, Cuesta-Linker T, Langner S, Müller H-G, Friedebold J. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis. Haemophilia. 1998;4(Suppl 3):25-32.
  4. Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E. Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor. Blood Reviews. 2019;38:10057. Accessed October 6, 2020.
  5. Budde U, Metzner HJ, Müller H-G. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost. 2006;32:626-635.
  6. Nichols WL, Jr., Chair. The diagnosis, evaluation, and management of von Willebrand disease. US Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 08-5832. December 2007.

You are now leaving the current website.

Do you want to continue?

Yes No